Skip to content

Insider · CIK 0001798117

Elliot Norry

officer

Files at ADAPY (Adaptimmune Therapeutics PLC). First filing Jan 15, 2025, latest Jan 17, 2025.

In brief

Elliot Norry files SEC Form 4 as officer at ADAPY (Adaptimmune Therapeutics PLC). Since Jan 15, 2025, Elliot Norry has reported 0 open-market buys worth $0 and 2 open-market sells worth $16k, the latest filed on Jan 17, 2025.

A track record needs three past buys with six months of prices behind them; Elliot Norry has 0, so none is measured yet.

The newest scored trade: sold $3,243 of ADAPY on Jan 17, 2025, filed Jan 17, 2025, scored 40 (moderate).

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 2
$0 bought, $16k sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

ADAPY: Adaptimmune Therapeutics PLC

ADAPYOct 9, 2026 · close 0.03

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
40Moderate
ADAPYsell 5
Adaptimmune Therapeutics PLC
$3,243
5,584 shares
-43%-
50Moderate
ADAPYsell 5
Adaptimmune Therapeutics PLC
$13k
22,195 shares
-219%-

Planned sales

Form 144 notices this insider filed before selling restricted or control stock, newest first.

FiledCompanySharesValueSale datePast 3 months
Jan 17, 2025 ADAPY
Adaptimmune Therapeutics PLC
5,584
0.00% of outstanding
$3,243Jan 17, 2025$13k
Jan 15, 2025 ADAPY
Adaptimmune Therapeutics PLC
12,392
0.00% of outstanding
$7,286Jan 13, 2025none

Transactions

Every row this insider has filed, 6 in all, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Feb 20, 2025ADAPY
Adaptimmune Therapeutics PLC
AGrant or award
Option to purchase Ordinary Sharesderivative
+1,612,032$0.00$01,612,032Feb 20, 2025
Feb 20, 2025ADAPY
Adaptimmune Therapeutics PLC
AGrant or award
Option to purchase Ordinary Sharesderivative
+1,074,696$0.00$01,074,696Feb 20, 2025
Jan 17, 2025ADAPY
Adaptimmune Therapeutics PLC
SOpen-market sale
American Depositary Shares representing Ordinary Shares
-5,584$0.58$3,2437,510Jan 17, 2025
Jan 13, 2025ADAPY
Adaptimmune Therapeutics PLC
SOpen-market sale
American Depositary Shares representing Ordinary Shares
-4,268$0.59$2,5095,845Jan 15, 2025
Jan 13, 2025ADAPY
Adaptimmune Therapeutics PLC
SOpen-market sale
American Depositary Shares representing Ordinary Shares
-8,124$0.59$4,77611,516Jan 15, 2025
Jan 15, 2025ADAPY
Adaptimmune Therapeutics PLC
SOpen-market sale
American Depositary Shares representing Ordinary Shares
-9,803$0.57$5,63513,756Jan 15, 2025

Questions about Elliot Norry

Answered from the filings on this page, as of the latest one.

Is Elliot Norry buying or selling?

Not in the last 12 months. Elliot Norry's latest open-market trade on SEC Form 4 was sold $3,243 of ADAPY on Jan 17, 2025.

How did Elliot Norry's past buys perform?

Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Elliot Norry has 0.

Where does Elliot Norry file Form 4?

Elliot Norry has filed Form 4 at ADAPY (Adaptimmune Therapeutics PLC) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Elliot Norry: insider trades and track record | InsiderTell